+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Radionuclide Drug Conjugate Market - Global Forecast 2026-2032- Product Image
Radionuclide Drug Conjugate Market - Global Forecast 2026-2032- Product Image
Sale

Radionuclide Drug Conjugate Market - Global Forecast 2026-2032

  • Report

  • 191 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6127152
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Radionuclide Drug Conjugate Market is projected to reach USD 906.01 Million in 2026. It is expected to continue growing at a CAGR of 10.77%, reaching USD 1.72 Billion by 2032.

Radionuclide Drug Conjugates: Executive Overview

Radionuclide drug conjugates (RDCs) combine a tumor-targeting ligand or antibody with a radioactive payload to deliver localized radiation to malignant cells. The field sits at the intersection of nuclear medicine, oncology, radiopharmaceutical manufacturing, diagnostic imaging, and specialized clinical logistics. Its development is shaped by target biology, isotope selection, linker stability, dosimetry, patient selection, and the availability of licensed handling and treatment facilities.

Clinical Integration Is Reshaping Radiopharmaceutical Development

RDC development is moving toward more integrated theranostic pathways in which molecular imaging supports target identification, treatment selection, and follow-up. Progress depends on demonstrating durable clinical benefit while managing radiation exposure, hematologic effects, organ toxicity, and manufacturing consistency. The field is also shifting toward more complex supply-chain models that coordinate isotope production, conjugation, quality control, cold-chain transport, and administration within narrow time windows.

Artificial Intelligence Strengthens Targeting, Dosimetry, and Operations

Artificial intelligence can support RDC programs by analyzing imaging and pathology data to identify target expression, stratify patients, and improve response assessment. Machine-learning methods may also assist dosimetry, treatment planning, radiographic interpretation, and prediction of toxicity, provided that training data are representative and clinically validated. Additional applications include batch-release analytics, scheduling, inventory coordination, and monitoring of isotope availability. Human oversight, explainability, privacy controls, and regulatory validation remain essential before algorithmic outputs are used in clinical decisions.

Regional Insights: Infrastructure and Regulation Define Adoption

North America benefits from established oncology networks, specialized nuclear-medicine capabilities, and active clinical research, while Latin America faces uneven access to isotope supply, imaging, and treatment infrastructure. Europe has strong academic and regulatory coordination, although national reimbursement and facility requirements differ across the region. The Middle East is expanding advanced-care capacity through selected medical hubs, whereas Africa remains constrained by uneven access to radiopharmacy services, trained personnel, and reliable logistics. Asia-Pacific combines sophisticated capabilities in countries such as Japan, Australia, South Korea, and China with substantial variation in infrastructure and access across neighboring markets.

Group Insights: Cooperation Can Reduce Development and Access Friction

ASEAN countries may benefit from coordinated training, regional referral pathways, and shared quality standards as radiopharmaceutical capabilities develop at different rates. BRICS members bring large and diverse patient populations, scientific capacity, and manufacturing potential, but regulatory alignment and infrastructure remain uneven. The European Union can leverage common scientific and regulatory frameworks while addressing national differences in reimbursement and service delivery. G7 economies provide advanced research, manufacturing, and clinical infrastructure, with continued emphasis on evidence quality and healthcare-system integration. GCC states are investing in specialized medical capacity and can serve as regional treatment hubs. NATO members may also benefit from interoperable logistics, radiation-safety expertise, and cross-border research collaboration where appropriate.

Country Insights: Capabilities Vary Across Research, Manufacturing, and Care Delivery

The United States and Canada have extensive oncology research and nuclear-medicine infrastructure, while the United Kingdom, France, Germany, Italy, and Spain combine established healthcare systems with differing regulatory, reimbursement, and isotope-supply arrangements. Australia has strong clinical research and specialist-care capabilities, although geographic distance makes logistics important. Japan and South Korea have advanced medical technology ecosystems, while China is expanding domestic radiopharmaceutical research, production, and clinical capacity. India is developing specialized oncology and nuclear-medicine services amid significant regional variation. Brazil and Mexico are strengthening access through major urban and academic centers. Russia retains scientific and nuclear capabilities, while broader access is influenced by supply-chain, regulatory, and international operating conditions.

Industry Leaders Should Prioritize Evidence, Resilience, and Patient Access

Leaders should establish development plans that connect target validation, companion imaging, dosimetry, toxicity management, and long-term follow-up from the outset. Manufacturing strategies should include qualified isotope sources, redundant logistics, validated release procedures, and contingency planning for decay-sensitive materials. Partnerships with hospitals and radiopharmacies can expand treatment readiness, while workforce programs should address nuclear medicine, radiation safety, pharmacy, oncology, and biomedical engineering skills. Artificial-intelligence tools should be introduced through controlled validation pathways with clear accountability. Finally, access planning should incorporate referral networks, patient travel support, equitable trial recruitment, and evidence packages suited to different national health systems.

Research Methodology: Evidence-Based Analysis of the RDC Ecosystem

This executive summary uses a structured assessment of radionuclide drug conjugates across biology, clinical development, manufacturing, regulation, infrastructure, logistics, and healthcare delivery. The analysis organizes insights by region, economic and political group, and country, emphasizing publicly verifiable scientific, regulatory, and institutional information. It distinguishes established capabilities from emerging activity and avoids unsupported numerical claims. Interpretations are framed around documented mechanisms, operational requirements, and recurring barriers to safe implementation rather than market estimates or company-specific positioning.

Conclusion: Coordinated Execution Will Determine RDC Impact

Radionuclide drug conjugates offer a targeted approach to radiotherapy, but clinical value depends on more than molecular design. Success requires reliable isotope access, robust conjugation and quality systems, accurate imaging and dosimetry, specialized treatment capacity, and coordinated patient management. Regional and country-level differences make adaptable implementation essential. Organizations that combine rigorous evidence generation with resilient operations, responsible artificial intelligence, and equitable access planning will be better positioned to translate RDC innovation into dependable patient care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Radionuclide Drug Conjugate Market, by Emission Type
7.1. Introduction
7.2. Alpha Emitter
7.3. Beta Emitter
8. Radionuclide Drug Conjugate Market, by Targeting Molecule
8.1. Introduction
8.2. Monoclonal Antibody
8.3. Peptide
8.4. Small Molecule
9. Radionuclide Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Neuroendocrine Tumor
9.3. Prostate Cancer
10. Radionuclide Drug Conjugate Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Radionuclide Drug Conjugate Market, by End User
11.1. Introduction
11.2. Hospital
11.2.1. Academic Hospital
11.2.2. Community Hospital
11.3. Research Institute
11.4. Specialty Clinic
12. Radionuclide Drug Conjugate Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Radionuclide Drug Conjugate Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Radionuclide Drug Conjugate Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Bayer AG
16.2. Curium Pharma S.A.
16.3. DongCheng Pharmaceutical Group
16.4. Eckert & Ziegler Strahlen- und Medizintechnik AG
16.5. Ion Beam Applications S.A.
16.6. Jubilant Pharmova Limited
16.7. Lantheus Holdings, Inc.
16.8. Nordion Inc.
16.9. Novartis AG
16.10. Point Biopharma Solutions, Inc.
16.11. Telix Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Radionuclide Drug Conjugate Market, Years Considered for the Study
FIGURE 2. Global Radionuclide Drug Conjugate Market, Research Design
FIGURE 3. Global Radionuclide Drug Conjugate Market, Research Framework
FIGURE 4. Global Radionuclide Drug Conjugate Market, Data Triangulation
FIGURE 5. Global Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Radionuclide Drug Conjugate Market Size, by Emission Type, 2025 vs 2032 (%)
FIGURE 7. Global Radionuclide Drug Conjugate Market Size, by Emission Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2025 vs 2032 (%)
FIGURE 9. Global Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Radionuclide Drug Conjugate Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 11. Global Radionuclide Drug Conjugate Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Radionuclide Drug Conjugate Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Radionuclide Drug Conjugate Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Radionuclide Drug Conjugate Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Radionuclide Drug Conjugate Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Radionuclide Drug Conjugate Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Radionuclide Drug Conjugate Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Radionuclide Drug Conjugate Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Radionuclide Drug Conjugate Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Radionuclide Drug Conjugate Market Segmentation & Coverage
TABLE 2. Global Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 3. Global Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 4. Global Alpha Emitter Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Alpha Emitter Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Alpha Emitter Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Beta Emitter Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Beta Emitter Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Beta Emitter Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 11. Global Monoclonal Antibody Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Monoclonal Antibody Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Monoclonal Antibody Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 21. Global Neuroendocrine Tumor Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Neuroendocrine Tumor Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Neuroendocrine Tumor Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 28. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 38. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Academic Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Academic Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Academic Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Community Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Community Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Community Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Research Institute Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Research Institute Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Research Institute Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Specialty Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Specialty Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 56. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 57. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 58. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 59. Asia-Pacific Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 60. Asia-Pacific Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 61. North America Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. North America Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 63. North America Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 64. North America Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 65. North America Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 66. North America Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 67. North America Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 68. Latin America Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Latin America Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 70. Latin America Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 71. Latin America Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 72. Latin America Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Latin America Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 74. Latin America Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 75. Europe Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Europe Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 77. Europe Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 78. Europe Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 79. Europe Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 80. Europe Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 81. Europe Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 82. Middle East Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Middle East Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 84. Middle East Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 85. Middle East Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 86. Middle East Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. Middle East Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 88. Middle East Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 89. Africa Radionuclide Drug Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Africa Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 91. Africa Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 92. Africa Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 93. Africa Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 94. Africa Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 95. Africa Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 96. Global Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. ASEAN Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. ASEAN Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 99. ASEAN Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 100. ASEAN Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 101. ASEAN Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 102. ASEAN Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. ASEAN Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 104. GCC Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. GCC Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 106. GCC Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 107. GCC Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 108. GCC Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 109. GCC Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. GCC Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 111. European Union Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. European Union Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 113. European Union Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 114. European Union Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 115. European Union Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 116. European Union Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. European Union Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 118. BRICS Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. BRICS Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 120. BRICS Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 121. BRICS Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. BRICS Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. BRICS Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 124. BRICS Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 125. G7 Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. G7 Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 127. G7 Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 128. G7 Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 129. G7 Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 130. G7 Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. G7 Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 132. NATO Radionuclide Drug Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. NATO Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 134. NATO Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 135. NATO Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 136. NATO Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 137. NATO Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 138. NATO Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 139. Global Radionuclide Drug Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. United States Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 141. United States Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 142. United States Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 143. United States Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 144. United States Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 145. United States Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 146. United States Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 147. Canada Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 148. Canada Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 149. Canada Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 150. Canada Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. Canada Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Canada Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. Canada Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 154. Mexico Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 155. Mexico Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 156. Mexico Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 157. Mexico Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 158. Mexico Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 159. Mexico Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Mexico Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 161. Brazil Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 162. Brazil Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 163. Brazil Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 164. Brazil Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. Brazil Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. Brazil Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Brazil Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 168. United Kingdom Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 170. United Kingdom Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 171. United Kingdom Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 172. United Kingdom Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 173. United Kingdom Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 174. United Kingdom Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 175. Germany Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 176. Germany Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 177. Germany Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 178. Germany Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Germany Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 180. Germany Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. Germany Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 182. France Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 183. France Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 184. France Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 185. France Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 186. France Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. France Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. France Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 189. Russia Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 191. Russia Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 192. Russia Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 193. Russia Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. Russia Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 195. Russia Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 196. Italy Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 197. Italy Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 198. Italy Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 199. Italy Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 200. Italy Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Italy Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. Italy Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 203. Spain Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 204. Spain Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 205. Spain Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 206. Spain Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 207. Spain Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 208. Spain Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 209. Spain Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 210. China Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 211. China Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 212. China Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 213. China Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 214. China Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. China Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. China Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 217. India Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 218. India Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 219. India Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 220. India Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 221. India Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. India Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 223. India Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 224. Japan Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 225. Japan Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 226. Japan Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 227. Japan Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 228. Japan Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 229. Japan Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. Japan Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 231. Australia Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 232. Australia Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 233. Australia Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 234. Australia Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Australia Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. Australia Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 237. Australia Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 238. South Korea Radionuclide Drug Conjugate Market Size, 2017-2032 (USD Million)
TABLE 239. South Korea Radionuclide Drug Conjugate Market Size, by Emission Type, 2017-2032 (USD Million)
TABLE 240. South Korea Radionuclide Drug Conjugate Market Size, by Targeting Molecule, 2017-2032 (USD Million)
TABLE 241. South Korea Radionuclide Drug Conjugate Market Size, by Indication, 2017-2032 (USD Million)
TABLE 242. South Korea Radionuclide Drug Conjugate Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 243. South Korea Radionuclide Drug Conjugate Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. South Korea Radionuclide Drug Conjugate Market Size, by Hospital, 2017-2032 (USD Million)
TABLE 245. Global Radionuclide Drug Conjugate Market Share, by Key Player, 2025
TABLE 246. Global Radionuclide Drug Conjugate Market, Key Experts

Companies Mentioned

  • Bayer AG
  • Curium Pharma S.A.
  • DongCheng Pharmaceutical Group
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Ion Beam Applications S.A.
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Nordion Inc.
  • Novartis AG
  • Point Biopharma Solutions, Inc.
  • Telix Pharmaceuticals Limited

Related Topics

Related Reports

Antibody Oligonucleotide Conjugates Drug Market - Global Forecast 2026-2032 - Product Image

Antibody Oligonucleotide Conjugates Drug Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Pediatric Drugs and Vaccines - Global Strategic Business Report - Product Image

Pediatric Drugs and Vaccines - Global Strategic Business Report

  • Report
  • 292 Pages
  • Global
From
CD19 Target Drug Market - Global Forecast 2026-2032 - Product Image

CD19 Target Drug Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Cyclooxygenase 1 Inhibitors - Global Strategic Business Report - Product Image

Cyclooxygenase 1 Inhibitors - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Rare Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Rare Disease Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 131 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.